Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-08-14
2007-08-14
Davis, Zinna N. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S139000, C546S144000
Reexamination Certificate
active
10450023
ABSTRACT:
The invention relates to novel compounds having the general formula: (I) and arc useful as selective ER-β ligands in the treatment or prophylaxis of Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis cardiovascular disease, rheumatoid arthritis or prostate cancer.
REFERENCES:
patent: 613879 (1994-09-01), None
patent: 1113007 (2001-07-01), None
patent: WO 9621656 (1996-07-01), None
patent: WO 0062765 (2000-10-01), None
patent: WO 00/55137 (2000-12-01), None
Chemical Abstracts, vol. 119, Abstract No. 72376, see RN 148234-96-2.
K. Nagarajan et al., “Antiimplantation Agents: Part IIa—1,2-Diaryl-1,2,3,4-tetrahydroisoquionolines b.c.,” Indian Journal of Chemistry, Hindustan CIBA-GEIGY Ltd., Research Centre (Goregaon East, Bombay 400063), p. 83-97, (Jul. 13, 1984).
G. Van Binst et al., “Benzo-and Indoloquinolizine derivatives-VII the dehydrogenation of enamines in quinolizidines,” Bull. Soc. Chim. Belg., Laboratorium voor Organische Chasole (Brussel), vol. 85 (No. 1-2), p. 1-9, (Sep. 1, 1976).
Charles K. Bradsher et al., “Schiff Bases as External and Internal Electrophiles in Reactions of Functionalized Organolithium Reagents. A New Route to Isoindoline Derivatives and 1,2,3,4-Tetrahydroisoquinolines 1,” J. Org. Chem., Paul M. Gross Chemical Laboratory, Duke University (Durham, North Carolina), vol. 46 (No. 2), p. 327-330, (Aug. 1, 1980).
K. Andrew Hedley et al., “Ring-opening Reactions of N-Aryl-1,2,3,4-tetrahydroisoquinoline Derivatives,” Tetrahedron, Pergamon Press plc (Great Britain), vol. 48 (No. 4), p. 743-750, (Nov. 15, 1991).
Rolf Paul et al., “1-Phenyl-2-phenethyl-1,2,3,4-tetrahydroisoquinolines. A New Series of Nonsteroidal Female Antifertility Agents,” J. Med. Chem., vol. 15 (No. 7), p. 720-726, (Nov. 2, 1971).
Barlaam Bernard
Dantzman Cathy
AstraZeneca AB
White & Case LLP
LandOfFree
Selective estrogen receptor-β ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective estrogen receptor-β ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective estrogen receptor-β ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3865665